Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in Post-acute Infection Syndromes Fulfilling ME/CFS Criteria (PIONEER)
NCT07724834Phase 2Not yet recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
A Phase 2 trial of inebilizumab in post-acute infection syndrome (PAIS), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), sponsored by Charité – Universitätsmedizin Berlin. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
post-acute infection syndrome (PAIS)myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT07724834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724834.